Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Napo Pharmaceuticals Inc.

This article was originally published in Start Up

Executive Summary

Napo Pharmaceuticals Inc. is developing its lead product crofelemer--a refined version of a natural extract from a South American tree-as a treatment for treating irritable bowel syndrome and other gastrointestinal indications including chronic diarrhea,. Napo plans to market medicines to developing countries before testing the waters back home.

You may also be interested in...

Salix Files Crofelemer NDA As Napo Seeks To Terminate Their Collaboration

Salix submitted an NDA for HIV-associated diarrhea; it has exclusive rights to market the drug for that indication under a collaboration agreement with Napo but Napo claims Salix has breached the deal by delaying development and commercialization.

Signs of Movement in IBS Drug Development

Despite Big Pharma's struggles, the availability of compounds developed for other pain indications could energize start-ups' interest in irritable bowel syndrome.

Sign-Ups Open For US FDA Premarket Progress Tracker Pilot

The pilot will allow at least a hundred device companies with 510(k)s under review this spring to test out the new industry submission-tracking dashboard.

Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts